Literature DB >> 16602074

Estimating treatment effects in randomized trials with treatment switching.

.   

Abstract

Mesh：

Year:  2006        PMID： 16602074     DOI： 10.1002/sim.2453

Source DB:  PubMed          Journal:  Stat Med        ISSN： 0277-6715            Impact factor:   2.373


× No keyword cloud information.
  5 in total

1.  Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.

Authors:  George D Demetri; Christopher R Garrett; Patrick Schöffski; Manisha H Shah; Jaap Verweij; Serge Leyvraz; Herbert I Hurwitz; Antonio Lopez Pousa; Axel Le Cesne; David Goldstein; Luis Paz-Ares; Jean-Yves Blay; Grant A McArthur; Qiang Casey Xu; Xin Huang; Charles S Harmon; Vanessa Tassell; Darrel P Cohen; Paolo G Casali
Journal:  Clin Cancer Res       Date:  2012-06-01       Impact factor: 12.531

2.  Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover.

Authors:  Huan Jin; Dongsheng Tu; Naiqing Zhao; Lois E Shepherd; Paul E Goss
Journal:  J Clin Oncol       Date:  2011-10-31       Impact factor: 44.544

3.  Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study.

Authors:  James P Morden; Paul C Lambert; Nicholas Latimer; Keith R Abrams; Allan J Wailoo
Journal:  BMC Med Res Methodol       Date:  2011-01-11       Impact factor: 4.615

4.  Estimation of treatment effects and model diagnostics with two-way time-varying treatment switching: an application to a head and neck study.

Authors:  Qingxia Chen; Fan Zhang; Ming-Hui Chen; Xiuyu Julie Cong
Journal:  Lifetime Data Anal       Date:  2020-03-03       Impact factor: 1.429

5.  Causal inference for long-term survival in randomised trials with treatment switching: Should re-censoring be applied when estimating counterfactual survival times?

Authors:  N R Latimer; I R White; K R Abrams; U Siebert
Journal:  Stat Methods Med Res       Date:  2018-06-25       Impact factor: 3.021
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.